The association between 17-hydroxyprogesterone caproate use and postpartum hemorrhage

Area of Science:

• Obstetrics and Gynecology
• Maternal-Fetal Medicine
• Pharmacology

Background:

• 17α-hydroxyprogesterone caproate (17P) is used to prevent recurrent preterm birth.
• The potential association between recent 17P administration and postpartum hemorrhage (PPH) requires investigation.

Purpose of the Study:

• To determine if 17P administration within seven days of delivery is linked to an increased risk of PPH.
• To analyze the safety profile of 17P concerning postpartum bleeding.

Main Methods:

• Retrospective cohort study of 221 women receiving 17P for preterm birth prevention (2010-2014).
• Women were grouped based on 17P administration within seven days of delivery.
• Bivariable and multivariable analyses were performed to assess PPH risk, adjusting for confounders.

Main Results:

• Of 221 women, 93 (42%) received 17P within seven days of delivery; 18 (7.8%) experienced PPH.
• No significant difference in PPH frequency was observed between groups (9.7% vs. 7.0%, p=0.478).
• Adjusted analysis showed no increased PPH risk (aOR 2.9, 95% CI 0.5-15.8).

Conclusions:

• Recent administration of 17P for preterm birth prevention is not associated with an increased risk of postpartum hemorrhage.
• Findings suggest 17P is safe concerning postpartum bleeding complications.